Class Action Lawsuit Against Drug Manufacturers of Actos in Canada
Accodring to MENAFN, a class action suit was launched on October 28 against Apotex Inc., Sandoz International GmbH, and Sandoz Canada Incorporated on behalf of users of generic versions of the diabetes treatment drug Actos.
ACTOS, used for treatment of Type 2 diabetes was found in a 2011 study to establish a clear causal link between increased rates of bladder cancer risk.
Among those that took Actos in the study, the risk for bladder cancer was found to be 30 percent higher among those with use of the drug between 12 to 24 months, and 50 percent higher among those whom used the drug greater than 24 months.
Class Action Suit Claims Defendants Knew Risks
Although Actos and its generic brands were required to update their labels following a year long review by Health Canada, Pioglitazone Hydrochloride still remains on the market.
In the class action suit filed with the Ontario Superior Court of Justice, allegations were put forth that the defendants knew of the increased risks of bladder cancer, failed to disclose those risks in a timely manner and failed to recall the drug after having such knowledge.
Contact an Experienced Drug Recall Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of recalled medications or pharmaceuticals, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.